Abstract:OBJECTIVEAseptic loosening of prosthesis is associated with periprosthetical osteolysis caused by osteoclast activation. Receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL)/receptor activator of NF-kappaB (RANK) signal pathway is fundamental in osteoclast activation. To determine whether RANKL antibody can inhibit inflammatory osteolysis in a osteolysis model of mouse.METHODSSixty female BALB/c mice (aged 8-10 weeks, weighing 18-20 g) were selected. The skull bone piece was harvested from 20 mice as the donor of bone graft; the subcutaneous air pouches (2 cm x 2 cm) models were established on the back of the other 40 mice and the skull bone piece was inserted into the air pouches. The 40 mice were equally divided into groups A (negative control group), B (positive control group), C (low-dose RANKL antibody group), and D (high-dose RANKL antibody group). At 1 day after bone graft, 0.5 mL PBS was injected into the pouch of group A, 0.5 mL PBS containing titanium particle into groups B, C, and D. At 2 days before the titanium particle was injected, RANKL antibody (0.1 mL) were injected into the pouch of group C (50 microg/mL) and group D (500 microg/mL), respectively every day for 2 days, and 0.1 mL PBS into groups A and B. At 14 days after bone implantation, the pouch membranes containing implanted bone were harvested for gross observation and histological analyse.RESULTSAll mice survived to the end of experiment, and incisions healed well. The gross observation showed that inflammatory responses, exudation, and vascular proliferation were obvious in group B, and were inconspicuous in groups A, C, and D. The histological analysis showed that significantly more infiltration of inflammatory cells, more obvious bone resorption, more bone collagen loss, and more positive staining area were observed in group B than in groups A, C, and D. There were significant differences in inflammatory cell number, pouch membrane thickness, bone collagen loss, and osteoclast content between group B and groups A, C, and D (P < 0.05).CONCLUSIONRANKL antibody can directly block RANKL/RANK signal pathway, which is an efficient therapy to inhibit bone absorption associated with implant wearing particles.

Recombinant Receptor Activator of Nuclear Factor Κb Exhibits More Marked Inhibitory Effects on Osteoclasts Compared with Recombinant Osteoprotegerin in Vitro and in Vivo.

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Effects of Recombinant Human Osteoprotegerin and Recombinant RANK Protein on the Differentiation of Osteoclast Precursors

Murine Rank Protein'S Inhibition of Bone Resorption

Recombinant Soluble Receptor Activator of Nuclear Factor-Kappab Inhibits Parathyroid Hormone-Induced Osteoclastogenesis in Vitro.

[Inhibitory Effect of Recombinant Receptor Activator of Nuclear Factor Kappab Protein on Bone Loss in Ovariectomized Mice].

Recombinant RANK Protein Inhibits Absorption Activity of Osteoclasts

Inhibition of the Osteoclast Activity with the Application of Recombinant Murine Rank Protein

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts

Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo*

Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function

Changes of receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in ovariectomized rats

Effect of recombinant human osteoprotegerin on rabbit osteoclasts in vitro

Effect of P38mapk Inhibition on Receptor Activator of Nuclear Factor-Κb Ligand and Osteoprotegerin Expressions in Osteoblasts

[Inhibition of Aseptic Loosening by Receptor Activator of Nuclear Factor Kappa B Ligand Antibody in Osteolysis Model of Mouse].

Inhibitory Effects of Osteoprotegerin on Osteoclast Formation and Function under Serum-Free Conditions

Effects of Recombinant Human Connective Tissue Growth Factor on the Expression of Osteoprotegerin and Receptor Activator of NF-κB Ligand in Human Osteoblasts

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats